Analytical Data
-
Gene name
PMP34
- Application
-
Alternative Names
PMP34;PMP34;Peroxisomal membrane Protein PMP34
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O43808
-
Expression Region
1-307aa
-
AA Sequence
MASVLSYESLVHAVAGAVGSVTAMTVFFPLDTARLRLQVDEKRKSKTTHMVLLEIIKEEGLLAPYRGWFPVISSLCCSNFVYFYTFNSLKALWVKGQHSTTGKDLVVGFVAGVVNVLLTTPLWVVNTRLKLQGAKFRNEDIVPTNYKGIIDAFHQIIRDEGISALWNGTFPSLLLVFNPAIQFMFYEGLKRQLLKKRMKLSSLDVFIIGAVAKAIATTVTYPLQTVQSILRFGRHRLNPENRTLGSLRNILYLLHQRVRRFGIMGLYKGLEAKLLQTVLTAALMFLVYEKLTAATFTVMGLKRAHQH
-
Molecular Weight
34.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PMP34, a recombinant protein derived from the pathogenic fungi of the genus *Pseudomonas*, has garnered significant attention in the field of biomedicine due to its potential role in immunological responses and disease mechanisms. As part of ongoing research into fungal pathogens, PMP34 is recognized for its structural characteristics that may facilitate its interaction with host immune systems. Studies have shown that this protein can elicit specific immune responses, making it a promising candidate for vaccine development or therapeutic strategies against fungal infections. Additionally, the exploration of PMP34's biochemical properties provides insights into its function and stability, which are crucial for its application in diagnostic tools. The growing prevalence of antifungal resistance has escalated the need for innovative approaches to combat fungal diseases, positioning PMP34 at the forefront of research aimed at understanding host-pathogen interactions. By elucidating the mechanisms by which PMP34 operates, researchers strive to unravel the complexities of fungal immunity, ultimately contributing to the development of novel therapeutic interventions and enhancing our arsenal against fungal infections.











